Jay Olson

“Oh, hey, congrats on all the progress, and thanks for taking our questions. We had a couple of questions, starting with 3246. Can you just talk about how you're thinking of positioning 3246 as a differentiated non-PSMA approach to metastatic CRPC?”

“We have another Rolutre gene question, and just wanted to follow up on something that you've commented on in the past, Marcio, that you've seen in the pooled mask data from Emerald that you've observed dynamics that are profoundly different from what a meta-analysis of historic DEE placebo groups could accommodate.”

“Since Loctorzi continues to deliver strong growth, you had the highest number of new patient starts since launch and improving treatment duration.”

“Since you have a number of new patents and multiple levers available to drive res difference sales growth, including potential combinations, how are you thinking about the peak sales magnitude and timeline to achieve peak sales?”

“Our question is related to the future of your psychiatry franchise with data readouts for OSEF Ampator and directly deemed expected next year. Do you have the commercial infrastructure that you would like to have to launch those two products?”